Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on November 5, 2015. The filing serves to announce the company's financial results for the quarter ended September 30, 2015. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the financial results are detailed in the attached press release (Exhibit 99.1), which is not included in the source text provided for this summary.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this Form 8-K. The document acts solely as a notification that results have been announced.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risks, or contingencies. It includes a standard disclaimer stating that the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is OvaScience, Inc., as the input metadata incorrectly listed "Tempest Therapeutics, Inc."
- Locate and review Exhibit 99.1 (Press Release dated November 5, 2015) to obtain actual financial figures for the quarter ended September 30, 2015.
- Confirm the company's principal executive office address is 9 Fourth Avenue, Waltham, MA 02451.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.